Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma-Reference-Cited by-同舟云学术

Resistance to Two Heterologous Neurotropic Oncolytic Viruses, Semliki Forest Virus and Vaccinia Virus, in Experimental Glioma

Published:2012-12-05 Issue:4 Volume:87 Page:2363-2366
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:Journal of Virology

Author:

Vaha-Koskela M. J. V.,Le Boeuf F.,Lemay C.,De Silva N.,Diallo J.-S.,Cox J.,Becker M.,Choi Y.,Ananth A.,Sellers C.,Breton S.,Roy D.,Falls T.,Brun J.,Hemminki A.,Hinkkanen A.,Bell J. C.

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Reference20 articles.

1. Neuro-oncology, a decade of temozolomide and beyond;Stupp;Expert. Rev. Anticancer Ther.,2010

2. Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses;Guo;Biochim. Biophys. Acta,2008

3. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice;Heikkilä;PLoS One,2010

4. Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models;Mättä;Int. J. Cancer,2007

5. Interferon-beta sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models;Ruotsalainen;Mol. Ther.,2012

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perspectives for applying Alphaviruses in antitumor therapy;Russian Journal of Infection and Immunity;2023-10-24

2. PKR induces TGF-β and limits oncolytic immune therapy;Journal for ImmunoTherapy of Cancer;2023-02

3. The intratumoral microbiome: Characterization methods and functional impact;Cancer Letters;2021-12

4. Resistance Mechanisms Influencing Oncolytic Virotherapy, a Systematic Analysis;Vaccines;2021-10-12

5. The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses;Oncolytic Virotherapy;2018-03